ERBB2/HER2 transmembrane and juxtamembrane domain mutations in cancer

ABSTRACT: In this study, we identified several recurrent activating HER2 somatic mutations in transmembrane and juxtamembrane domain in multiple cancers and demonstrate that patients carryingthese mutations are candidates for anti-HER2 therapy. We have also identified a germline mutation in HER2 transmembrane domain.

PROVIDER: EGAS00001003213 | EGA |

REPOSITORIES: EGA